肿瘤组蛋白序列变异统一分类框架:专家共识提案
该专家共识指出,组蛋白基因序列变异因N端甲硫氨酸切除导致传统命名与HGVS指南不一致,造成病理报告混乱。文章综述H3-3A基因变异肿瘤实体,提出基于HGVS原则的统一命名标准,呼吁期刊和报告采纳。
要点
- 组蛋白变异命名需统一遵循HGVS原则以避免混淆。
- 传统命名省略起始甲硫氨酸,与HGVS编号不同。
- 建议科学期刊和病理报告采用新命名标准。
核心结论
- 组蛋白序列变异应按照HGVS原则统一命名,以消除歧义。
研究设计与样本
- 专家共识提案,基于文献综述提出命名标准。
主要发现
- 组蛋白传统命名省略N端甲硫氨酸,与HGVS编号不一致。
- 下一代测序报告遵循HGVS,导致组蛋白变异描述不明确。
- 两种命名共存给病理学家、肿瘤学家和研究人员带来困惑。
关键数值与推荐
- 提出根据HGVS原则明确描述组蛋白序列变异的报告标准。
临床怎么用
- 病理报告应采用新命名标准,确保组蛋白变异描述明确。
- 科学期刊应采纳新命名法,促进一致性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The description of genetic alterations in tumours is of increasing importance. In human genetics, and in pathology reports, sequence alterations are given using the human genome variation society (HGVS) guidelines for the description of such variants. However, there is less adherence to these guidelines for sequence variations in histone genes. Due to early cleavage of the N-terminal methionine in most histones, the description of histone sequence alterations follows their own nomenclature and differs from the HGVS-compliant numbering by omitting this first amino acid. Next generation sequencing reports, however, follow the HGVS guidelines and as a result, an unambiguous description of sequence variants in histones cannot be provided. The coexistence of these two nomenclatures leads to confusions for pathologists, oncologists, and researchers. This review provides an overview of tumour entities with sequence alterations of the H3-3A gene (HGNC ID = HGNC:4764), highlights the problems associated with the coexistence of these two nomenclatures, and proposes a standard for the reporting of histone sequence variants that allows an unambiguous description of these variants according to HGVS principles. We hope that scientific journals will adopt the new notation, and that both geneticists and pathologists will include it in their reports. © 2021 The Authors. The Journal of Pathology published by John Wiley & Sons, Ltd. on behalf of The Pathological Society of Great Britain and Ireland.
引用
- Leske H, Dalgleish R, Lazar AJ, et al. A common classification framework for histone sequence alterations in tumours: an expert consensus proposal. J Pathol. 2021. PMID: 33779999. doi:10.1002/path.5666
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。